Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fulcrum Therapeutics Inc
(NQ:
FULC
)
7.750
+0.100 (+1.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fulcrum Therapeutics Inc
< Previous
1
2
3
4
Next >
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 4/12
April 12, 2024
Via
Investor Brand Network
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
March 28, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
March 18, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 3/6
March 06, 2024
Via
Investor Brand Network
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
February 27, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
February 20, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
November 09, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near the Top of Equities by Percentage Gain on 11/7
November 07, 2023
Via
Investor Brand Network
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
November 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
October 31, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
September 22, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ:FULC Long Term Investor Alert: Investigation of Potential Wrongdoing at Fulcrum Therapeutics, Inc.
September 14, 2023
San Diego, CA -- (SBWIRE) -- 09/14/2023 -- Certain directors of Fulcrum Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
September 13, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...
Via
FinancialNewsMedia
Exposures
Product Safety
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
September 07, 2023
Enrolled 260 patients; topline data expected in the fourth quarter of 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near Top of Volume Charts in Tuesday Trading
August 22, 2023
Via
Investor Brand Network
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
August 22, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
August 03, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Appoints Chief Financial Officer
August 03, 2023
— Alan A. Musso appointed as CFO effective August 7, 2023 —
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
July 27, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
July 10, 2023
CAMP4 Therapeutics grants exclusive rights to advance novel therapies for Diamond-Blackfan Anemia
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (FULC)
June 26, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.